New Phase 3 Study Planned for Possible Treatment of Agitation Linked to Alzheimer’s

New Phase 3 Study Planned for Possible Treatment of Agitation Linked to Alzheimer’s
Otsuka Pharmaceutical announced that it and Lundbeck will launch a third Phase 3 clinical trial of brexpiprazole to possibly treat agitation in patients with dementia linked to probable Alzheimer’s disease. Brexpiprazole, under the brand name Rexulti, was approved in the United States to treat people with schizophrenia and as an adjunct treatment for patients with major depressive disorder (MDD) in

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *